Viralytics Ltd (VLA)

Currency in AUD
1.745
0.000(0.00%)
Closed·
Showing Viralytics Ltd historical data. For real-time data please try another search
Day's Range
1.7451.750
52 wk Range
0.0001.750
Key Statistics
Prev. Close
1.745
Open
1.745
Day's Range
1.745-1.75
52 wk Range
0-0
Volume
-
Average Volume (3m)
651.37K
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Viralytics Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Viralytics Ltd Company Profile

Viralytics Limited, a biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies in Australia and internationally. The company’s lead investigational product is CAVATAK, a proprietary formulation of an oncolytic common cold virus that is in Phase Ib clinical trials for the treatment of melanoma, and lung and bladder cancer; Phase II clinical trials for the treatment of late stage melanoma; and in pre-clinical studies for the treatment of prostate and breast cancer, multiple myeloma, pancreatic cancer, malignant glioma, acute myeloid leukemia, and chronic lymphocytic leukemia. It is also developing EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia. As of June 20, 2018, Viralytics Limited operates as a subsidiary of Merck & Co. Inc.

Viralytics Ltd Earnings Call Summary for Q4/2024

  • Product sales up 13% YoY to €163.3M, with IXIARO sales surging 28% to €94.1M and DUKORAL sales growing 8% to €32.3M
  • Operating profit of €20.7M, reversing previous year's €82.1M loss; strong cash position of €168M maintained
  • Chikungunya vaccine launch contributes €3.7M in initial sales; company forecasts €170-180M product sales for 2025
  • R&D investment of €90-100M planned, focusing on advancing Lyme disease vaccine to Phase III trials
  • CEO expresses confidence in future growth, with potential profitability by 2027 contingent on Lyme vaccine success
Last Updated: 20/03/2025, 16:26
Read Full Transcript

Earnings

Latest Release
Feb 20, 2019
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

VLA Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.